GlassScriptPhysician profile
Jared Anthony Crook
NPI 1417420498
$2,434.95
in general payments reported to CMS, 2019-2025
40 companies · $1,846 in 2025
The $1,846 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $70.94 · 2022: $46.30 · 2024: $472 · 2025: $1,846.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,219 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,218.71 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $349.21 | 2021-2025 | |
| Aveo Pharmaceuticals, INC. | $335.48 | 2024-2025 | |
| Tempus Ai, INC | $196.74 | 2024-2025 | Xt Cdx |
| Astrazeneca Pharmaceuticals LP | $141.31 | 2025 | Enhertu, Imjudo, Imfinzi |
| Myriad Genetic Laboratories, INC. | $131.01 | 2024 | Myrisk |
| Pfizer INC. | $112.34 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $90.43 | 2024-2025 | |
| Eisai INC. | $80.59 | 2025 | |
| Geron Corporation | $74.31 | 2025 | Rytelo |
| Genentech USA, INC. | $73.82 | 2025 | Polivy, Itovebi |
| Glaxosmithkline, LLC. | $64.77 | 2024-2025 | Jemperli, Zejula |
| Novartis Pharmaceuticals Corporation | $59.53 | 2025 | |
| Alexion Pharmaceuticals, INC. | $56.93 | 2024-2025 | Ultomiris |
| Karyopharm Therapeutics INC. | $41.27 | 2025 | Xpovio |
| Incyte Corporation | $38.43 | 2025 | Monjuvi, Niktimvo, Jakafi |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $35.81 | 2025 | Cabometyx |
| Regeneron Healthcare Solutions, INC. | $35.73 | 2025 | Libtayo |
| Amgen INC. | $32.54 | 2022 | |
| Pharmaessentia USA Corporation | $32.11 | 2025 | Besremi |
| Jazz Pharmaceuticals INC. | $28.47 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $26.86 | 2021 | |
| Janssen Biotech, INC. | $24.83 | 2025 | Balversa, Akeega, Erleada |
| Springworks Therapeutics, INC. | $24.69 | 2025 | Ogsiveo |
| Taiho Oncology, INC. | $24.27 | 2025 | |
| Lilly USA, LLC | $23.78 | 2025 | Verzenio, Jaypirca |
| Genzyme Corporation | $22.78 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.70 | 2024 | Ninlaro |
| Avanos Medical | $22.69 | 2024 | Standard Rf Disposables |
| Genmab U.S., INC. | $22.26 | 2025 | Epkinly |
| Immunocore Limited | $22.14 | 2025 | Kimmtrak |
| Stemline Therapeutics INC. | $22.07 | 2025 | Elzonris |
| E.R. Squibb & Sons, L.L.C. | $21.59 | 2025 | |
| Merck Sharp & Dohme LLC | $21.42 | 2025 | Lynparza, Keytruda |
| Sobi, INC | $19.67 | 2025 | |
| Apellis Pharmaceuticals, INC. | $18.93 | 2025 | Empaveli |
| Daiichi Sankyo INC. | $18.51 | 2025 | Datroway |
| Syndax Pharmaceuticals, INC. | $18.41 | 2025 | |
| Blue Earth Diagnostics | $17.78 | 2025 | Posluma |
| Caris Mpi, INC. | $14.73 | 2025 | Mi Cancer Seek |
| Recordati_rare_diseases_inc. | $14.01 | 2025 | Sylvant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Crook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.